Omalizumab for peanut hypersensitivity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Mar 2019: Trial registered, NCT03881696
  2. 22 Jul 2019: Trial started, NCT03881696

The trials

NCT03881696: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

State
Completed
Phase
Phase 3
People
458 taking part
Started
22 Jul 2019
Primary completion
13 Mar 2023
Arms
Stage 1:Omalizumab as Monotherapy, Stage 1: Omalizumab OLE, Stage 2: Omalizumab
Results
Posted on the registry
  1. 19 Mar 2019: Trial registered
  2. 22 Jul 2019: Trial started
  3. 4 Jun 2024: Trial results posted
  4. 1 Jul 2025: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Omalizumab Injection, Xolair.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.